Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016


  • Products Id :- GMDHC0520TDB
  • |
  • Pages: 221
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016', provides in depth analysis on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)

- The report reviews Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Overview 8

Therapeutics Development 9

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Stage of Development 9

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Therapy Area 10

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Indication 11

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Companies 18

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Universities/Institutes 34

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Therapeutics Assessment 36

Assessment by Monotherapy/Combination Products 36

Assessment by Mechanism of Action 37

Assessment by Route of Administration 39

Assessment by Molecule Type 41

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Companies Involved in Therapeutics Development 43

Aduro BioTech, Inc. 43

Agenus, Inc. 44

Aurigene Discovery Technologies Limited 45

BeiGene, Ltd. 46

Beijing Hanmi Pharmaceutical Co., Ltd. 47

BIOCAD 48

Cellular Biomedicine Group, Inc. 49

CytomX Therapeutics, Inc. 50

Eli Lilly and Company 51

Enumeral Biomedical Holdings, Inc. 52

Immunovo BV 53

Jiangsu Hengrui Medicine Co., Ltd. 54

Jounce Therapeutics, Inc. 55

Les Laboratoires Servier SAS 56

MacroGenics, Inc. 57

MD Biosciences GmbH 58

MedImmune, LLC 59

Merck & Co., Inc. 60

Molecular Partners AG 62

Novartis AG 63

Ono Pharmaceutical Co., Ltd. 64

Pfizer Inc. 68

PharmaEssentia Corporation 69

Pieris Pharmaceuticals Inc 70

Regeneron Pharmaceuticals Inc 71

Sutro Biopharma, Inc. 72

Symphogen A/S 73

Tasly Pharmaceutical Group Co., Ltd. 74

Tesaro, Inc. 75

Theravectys SA 76

Tikcro Technologies, Ltd. 77

Vyriad 78

Xencor, Inc. 79

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drug Profiles 80

AM-0001 - Drug Profile 80

AMP-224 - Drug Profile 81

Anti-PD1 Monoclonal Antibody + Cellular Immunotherapy for Glioblastoma - Drug Profile 83

AUR-012 - Drug Profile 84

BGB-108 - Drug Profile 85

BGBA-317 - Drug Profile 86

Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile 87

Drug to Inhibit PD-1, Gal-9 and TIM-3 for Solid Tumor - Drug Profile 88

durvalumab + MEDI-0680 - Drug Profile 89

ENUM-003 - Drug Profile 90

ENUM-388D4 - Drug Profile 92

GXP-2 - Drug Profile 93

IBI-308 - Drug Profile 94

JS-001 - Drug Profile 95

MD-402 - Drug Profile 96

mDX-400 - Drug Profile 97

MEDI-0680 - Drug Profile 98

MGD-013 - Drug Profile 99

Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile 100

Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile 101

Monoclonal Antibodies to Antagonize PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile 102

Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile 103

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 104

Monoclonal Antibody to Antagonize PD-1 for Autoimmune Disorders and Oncology - Drug Profile 105

Monoclonal Antibody to Antagonize PD-1 for Non-Small Cell Lung Cancer - Drug Profile 106

Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 107

Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 108

Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 109

Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 110

Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 111

Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile 112

Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology - Drug Profile 113

Monoclonal Antibody to Inhibit PD-1 for Cancer - Drug Profile 114

Monoclonal Antibody to Inhibit PD-1 for HIV - Drug Profile 115

Monoclonal Antibody to Inhibit PD-1 for Oncology - Drug Profile 116

Monocloncal Antibody to Inhibit PD-1 for Oncology - Drug Profile 117

nivolumab - Drug Profile 118

Oncolytic Virus to Activate IFNb for Head and Neck Cancer and Lewis Lung Cancer - Drug Profile 148

pazopanib hydrochloride + pembrolizumab - Drug Profile 149

PD-1 Antagonist + ropeginterferon alfa-2b - Drug Profile 150

PDR-001 - Drug Profile 151

PEGMP-7 - Drug Profile 152

pembrolizumab - Drug Profile 153

PF-06801591 - Drug Profile 185

PRS-332 - Drug Profile 186

Recombinant Protein to Inhibit VEGF-A and PD1 for Solid Tumor and Hematological Malignancies - Drug Profile 187

REGN-2810 - Drug Profile 188

SHR-1210 - Drug Profile 190

SNPD-07 - Drug Profile 191

STIA-1110 - Drug Profile 192

TSR-042 - Drug Profile 193

Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 194

Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 195

Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 196

XmAb-20717 - Drug Profile 197

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Dormant Projects 198

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Discontinued Products 199

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Featured News & Press Releases 200

Appendix 216

Methodology 216

Coverage 216

Secondary Research 216

Primary Research 216

Expert Panel Validation 216

Contact Us 216

Disclaimer 217

List of Figures

Number of Products under Development for, H2 2016 13

Number of Products under Development by Therapy Area, H2 2016 14

Number of Products under Development by Indication, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Early Stage Products, H2 2016 20

Assessment by Monotherapy/Combination Products, H2 2016 40

Number of Products by Mechanism of Actions, H2 2016 41

Number of Products by Stage and Mechanism of Actions, H2 2016 41

Number of Products by Routes of Administration, H2 2016 43

Number of Products by Stage and Routes of Administration, H2 2016 43

Number of Products by Molecule Types, H2 2016 45

Number of Products by Stage and Molecule Type, H2 2016 45

List of Tables

Number of Products under Development for, H2 2016 13

Number of Products under Development by Therapy Area, H2 2016 14

Number of Products under Development by Indication, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Early Stage Products, H2 2016 20

Comparative Analysis by Unknown Stage Development, H2 2016 21

Number of Products under Development by Companies, H2 2016 22

Number of Products under Development by Companies, H2 2016 (Contd..1) 23

Products under Development by Companies, H2 2016 24

Products under Development by Companies, H2 2016 (Contd..1) 25

Products under Development by Companies, H2 2016 (Contd..2) 26

Products under Development by Companies, H2 2016 (Contd..3) 27

Products under Development by Companies, H2 2016 (Contd..4) 28

Products under Development by Companies, H2 2016 (Contd..5) 29

Products under Development by Companies, H2 2016 (Contd..6) 30

Products under Development by Companies, H2 2016 (Contd..7) 31

Products under Development by Companies, H2 2016 (Contd..8) 32

Products under Development by Companies, H2 2016 (Contd..9) 33

Products under Development by Companies, H2 2016 (Contd..10) 34

Products under Development by Companies, H2 2016 (Contd..11) 35

Products under Development by Companies, H2 2016 (Contd..12) 36

Products under Development by Companies, H2 2016 (Contd..13) 37

Number of Products under Investigation by Universities/Institutes, H2 2016 38

Products under Investigation by Universities/Institutes, H2 2016 39

Assessment by Monotherapy/Combination Products, H2 2016 40

Number of Products by Stage and Mechanism of Action, H2 2016 42

Number of Products by Stage and Route of Administration, H2 2016 44

Number of Products by Stage and Molecule Type, H2 2016 46

Pipeline by Aduro BioTech, Inc., H2 2016 47

Pipeline by Agenus, Inc., H2 2016 48

Pipeline by Aurigene Discovery Technologies Limited, H2 2016 49

Pipeline by BeiGene, Ltd., H2 2016 50

Pipeline by Beijing Hanmi Pharmaceutical Co., Ltd., H2 2016 51

Pipeline by BIOCAD, H2 2016 52

Pipeline by Cellular Biomedicine Group, Inc., H2 2016 53

Pipeline by CytomX Therapeutics, Inc., H2 2016 54

Pipeline by Eli Lilly and Company, H2 2016 55

Pipeline by Enumeral Biomedical Holdings, Inc., H2 2016 56

Pipeline by Immunovo BV, H2 2016 57

Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 58

Pipeline by Jounce Therapeutics, Inc., H2 2016 59

Pipeline by Les Laboratoires Servier SAS, H2 2016 60

Pipeline by MacroGenics, Inc., H2 2016 61

Pipeline by MD Biosciences GmbH, H2 2016 62

Pipeline by MedImmune, LLC, H2 2016 63

Pipeline by Merck & Co., Inc., H2 2016 64

Pipeline by Molecular Partners AG, H2 2016 66

Pipeline by Novartis AG, H2 2016 67

Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 68

Pipeline by Pfizer Inc., H2 2016 72

Pipeline by PharmaEssentia Corporation, H2 2016 73

Pipeline by Pieris Pharmaceuticals Inc, H2 2016 74

Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 75

Pipeline by Sutro Biopharma, Inc., H2 2016 76

Pipeline by Symphogen A/S, H2 2016 77

Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016 78

Pipeline by Tesaro, Inc., H2 2016 79

Pipeline by Theravectys SA, H2 2016 80

Pipeline by Tikcro Technologies, Ltd., H2 2016 81

Pipeline by Vyriad, H2 2016 82

Pipeline by Xencor, Inc., H2 2016 83

Dormant Projects, H2 2016 202

Discontinued Products, H2 2016 203

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aduro BioTech, Inc.

Agenus, Inc.

Aurigene Discovery Technologies Limited

BeiGene, Ltd.

Beijing Hanmi Pharmaceutical Co., Ltd.

BIOCAD

Cellular Biomedicine Group, Inc.

CytomX Therapeutics, Inc.

Eli Lilly and Company

Enumeral Biomedical Holdings, Inc.

Immunovo BV

Jiangsu Hengrui Medicine Co., Ltd.

Jounce Therapeutics, Inc.

Les Laboratoires Servier SAS

MacroGenics, Inc.

MD Biosciences GmbH

MedImmune, LLC

Merck & Co., Inc.

Molecular Partners AG

Novartis AG

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

PharmaEssentia Corporation

Pieris Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Sutro Biopharma, Inc.

Symphogen A/S

Tasly Pharmaceutical Group Co., Ltd.

Tesaro, Inc.

Theravectys SA

Tikcro Technologies, Ltd.

Vyriad

Xencor, Inc.

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Therapeutic Products under Development, Key Players in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Therapeutics, Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Pipeline Overview, Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Pipeline, Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Pipeline Assessment

select a license

Single User License
USD 3500 INR 226030
Site License
USD 7000 INR 452060
Corporate User License
USD 10500 INR 678090

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com